Does L-asparaginase influence efficacy or toxicity when added to a standard CHOP protocol for dogs with lymphoma?

Journal of Veterinary Internal Medicine

Volumn 19, Issue 5, 2005, Pages 732-736

  MacDonald, Valerie S ^a   Thamm, Douglas H ^a,b   Kurzman, Ilene D ^a,b   Turek, Michelle M ^a   Vail, David M ^a,b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Canine; Chemotherapy; Induction; Lymphosarcoma; Remission

Indexed keywords

ANTINEOPLASTIC AGENT; ASPARAGINASE;

ANIMAL; ANIMAL DISEASE; ARTICLE; BLOOD ANALYSIS; BLOOD CELL COUNT; CANCER STAGING; DISEASE FREE SURVIVAL; DOG; DOG DISEASE; FEMALE; LYMPHOMA; MALE; MORTALITY; REMISSION; SURVIVAL; URINALYSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARAGINASE; BLOOD CELL COUNT; BLOOD CHEMICAL ANALYSIS; DISEASE-FREE SURVIVAL; DOG DISEASES; DOGS; FEMALE; LYMPHOMA; MALE; NEOPLASM STAGING; REMISSION INDUCTION; SURVIVAL ANALYSIS; URINALYSIS;

CANIS FAMILIARIS;

EID: 26844537699     PISSN: 08916640     EISSN: None     Source Type: Journal    
DOI: 10.1892/0891-6640(2005)19[732:DLIEOT]2.0.CO;2     Document Type: Article

References (20)

1. Vail DM, MacEwen EG, Young K. Canine lymphoma and lymphoid leukemias. In: Withrow SJ, MacEwen EG, eds. Small Animal Clinical Oncology, 3rd ed. Philadelphia, PA: WB Saunders; 2001:558-590.
2. Rogers KS. L-Asparaginase for treatment of lymphoid neoplasia in dogs. J Am Vet Med Assoc 1989;194:1626-1630.
3. Furman L, Camitta BM, Jaffe N, et al. Development of an effective treatment program for childhood acute lymphocytic leukemia: A preliminary report. Med Pediatr Oncol 1976;2:157-166.
4. Rowinsky EK, Donehower RC. Antimicrotubule agents. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 5th ed. Philadelphia, PA: Lippincott-Raven; 1997:471.
5. Keating MJ, Holmes R, Lerner S, Ho DH. L-Asparaginase and PEG asparaginase - Past, present, and future. Leuk Lymphoma 1993;10:153-157.
6. Rogers KS, Barton CL, Benson PA, Green RA. Effects of single-dose L-asparaginase on coagulation values in healthy dogs and dogs with lymphoma. Am J Vet Res 1992;53:580-584.
7. Valerius KD, Ogilvie GK, Mallinckrodt CH, Getzy DM. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995). J Am Vet Med Assoc 1997;210:512-516.
8. Valerius KD, Ogilvie GK, Fettman MJ, et al. Comparison of the effects of asparaginase administered subcutaneously versus intramuscularly for treatment of multicentric lymphoma in dogs receiving doxorubicin. J Am Vet Med Assoc 1999;214:353-356.
9. Owen L. TNM Classification of Tumors in Domestic Animals. Geneva, Switzerland: World Health Organization; 1980:46-47.
10. Veterianary Co-operative Oncology Group. Common terminology criteria for adverse events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:194-213.
11. Siegel S. Nonparametric Statistics for the Behavioural Sciences. Tokyo, Japan: McGraw-Hill; 1959:96-104.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-462.
13. Breslow N. A generalized Kruskal-Wallis test for comparing samples subject to unequal patters of censorship. Biometricka 1970;57:579-583.
14. Teske E, vanHeerde P, Rutteman GR, et al. Prognostic factors for treatment of malignant lymphoma in dogs. J Am Vet Med Assoc 1994;205:1722-1728.
15. Keller ET, MacEwen EG, Rosenthal RC, et al. Evaluation of prognostic factors and sequential combination chemotherapy with doxorubicin for canine lymphoma. J Vet Intern Med 1993;7:289-295.
16. Garret LD, Thamm DH, Chun R, et al. Evaluation of a 6-month chemotherapy protocol with no maintenance therapy for dogs with lymphoma. J Vet Intern Med 2002;16:704-709.
17. Myers NC, Moore AS, Rand WM, et al. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Intern Med 1997;11:333-339.
18. Moore AS, Cotter SM, Rand WM, et al. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Intern Med 2001;15:348-354.
19. Boyce KL, Kitechell BE. Treatment of canine lymphoma with COPLA/LVP. J Am Anim Hosp Assoc 2000;36:395-403.
20. Northrup NC, Rassnick KM, Snyder LA, et al. Neutropenia associated with vincristine and L-asparaginase induction chemotherapy for canine lymphoma. J Vet Intern Med. 2002;16:570-575.